MetaCap

Acurx Pharmaceuticals (ACXP) vs GT Biopharma (GTBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GT Biopharma is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACXP-20.00%GTBP-52.26%
+22%-17%-56%
Oct 7, 20261 yearNov 20, 2026
ACXP-18.11%GTBP-55.69%
+8%-25%-59%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACXP versus GTBP key metrics
MetricACXPGTBP
Share price$1.04$2.96
Market cap$6.30M$6.33M
1-day change+0.97%-6.92%
YTD return—+277.07%
1-year return—+303.27%
5-year return—-97.77%
EPS (TTM)$-1.90$-128.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.97M$-28.35M
52-week high$7.54$23.60
52-week low$0.90$2.87
Distance from 52-week high-86.21%-87.46%
Analyst consensusstrong_buynone
Avg. price target upside+1534.62%+2433.78%
Average volume97.29K78.16K
Shares outstanding6.06M2.14M
Employees41
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acurx Pharmaceuticals

ACXP stock →

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About GT Biopharma

GTBP stock →

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ACXP vs GTBP FAQ

Which is bigger, Acurx Pharmaceuticals or GT Biopharma?

GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $6.30M for Acurx Pharmaceuticals (ACXP).

Are Acurx Pharmaceuticals and GT Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons